Bayer’s Pipeline Delivers Two Breakthroughs as Supreme Court Weighs Roundup’s Future

Bayer’s Asundexian cuts stroke risk 26% in landmark trial, Kerendia gains EU approval, and the Supreme Court hears Roundup preemption case—shaping the company’s future.

The German life-sciences group is navigating a defining moment, with clinical wins in cardiology and neurology colliding against a high-stakes legal showdown in Washington. While investors track the share price’s steady recovery from last year’s lows, the real action is unfolding both in courtrooms and in late-stage drug trials.

A New Stroke Prevention Standard Emerges

Bayer’s experimental anticoagulant Asundexian has delivered what the company calls a landmark result. Full data from the Phase III OCEANIC-STROKE trial, published in the New England Journal of Medicine in April, showed the drug reduced ischemic strokes by 26 percent compared with placebo, without increasing bleeding risk. That makes it the first FXIa inhibitor to successfully complete a Phase III study, a milestone that has already earned the compound Fast-Track designation from the US Food and Drug Administration.

The drug is now positioned as a serious contender in secondary stroke prevention, a market analysts see as a potential blockbuster opportunity. Bayer has not yet disclosed a timeline for regulatory filings, but the clinical profile suggests a clear path toward approval.

Kerendia Expands Its Reach

Alongside Asundexian, Bayer’s kidney drug Kerendia (finerenone) is gaining ground. The European Commission has approved it for a new indication: heart failure in adults with a left ventricular ejection fraction of 40 percent or more. Roughly half of the 15 million Europeans living with heart failure fall into this category, giving the drug access to a large and medically underserved patient pool.

Kerendia generated €829 million in sales last year, and Bayer continues to target long-term peak annual revenue of €3 billion. The company also reported a fifth positive Phase III study, FIND-CKD, which showed finerenone slows disease progression in non-diabetic chronic kidney disease. Bayer plans to submit those data to health authorities in the coming months.

The oncology drug Nubeqa, meanwhile, grew 57 percent to €2.4 billion in sales, providing additional momentum as Bayer prepares for the patent cliff on its current blockbusters Xarelto and Eylea. Management has flagged 2026 as the final year of significant headwinds from those expirations.

The Supreme Court Hearing That Could Reshape Liability

All of this pharmaceutical progress is unfolding against a legal backdrop that remains the single biggest overhang on Bayer’s stock. On Monday, the US Supreme Court began oral arguments in the case Durnell v. Monsanto, which centers on whether federal pesticide law preempts state-level failure-to-warn claims over Roundup.

Bayer argues that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) bars states from allowing lawsuits because the Environmental Protection Agency does not require a cancer warning label on glyphosate-based herbicides. The Trump administration has backed that argument in a friend-of-the-court brief filed by the Solicitor General.

The case matters because lower courts are split. The Third Circuit ruled that federal law preempts state claims, while the Ninth and Eleventh Circuits reached the opposite conclusion. A Supreme Court ruling in Bayer’s favor would not only weaken the roughly 65,000 outstanding Roundup lawsuits nationwide but also set a precedent that could reshape product liability law for decades.

A decision is expected by the end of June.

A Settlement Offer on the Table

In parallel, Bayer is pushing ahead with an out-of-court resolution. A federal judge in Missouri has preliminarily approved a proposed settlement worth roughly $7.25 billion, designed to resolve both current and future claims that Roundup causes cancer — an allegation the company denies. Claimants have until early June to opt out of the deal.

The financial burden is already visible. Bayer has budgeted around €5 billion for litigation-related payouts this year, which is expected to drag free cash flow to between negative €1.5 billion and negative €2.5 billion. That is a sharp contrast to the improving balance sheet elsewhere: net debt fell last year to just under €30 billion, and management has reaffirmed its full-year revenue guidance of €45 billion to €47 billion, with new US tariffs on pharmaceutical imports already factored in.

Market Reaction: Calm Before the Verdict

The share price reflects a market that is cautiously optimistic but not yet celebratory. At €38.50, the stock is trading comfortably above its 200-day moving average but remains roughly 22 percent below its 52-week high of €49.17. Over the past twelve months, however, the shares have gained nearly 68 percent, driven by the pipeline progress and hopes for a legal resolution.

Monday’s slight dip at the open was a technical adjustment: Bayer’s shares began trading ex-dividend, with the proposed €0.11 per share payout scheduled for April 29.

For now, the focus shifts back to Washington. The Supreme Court’s ruling in June will determine whether Bayer’s pharmaceutical renaissance can proceed without the drag of an endless legal war. If the justices side with the company, the path forward looks markedly clearer — both for the stock and for the strategy of transforming Bayer into a pure-play life sciences powerhouse.